Structures available for Coagulation Factor X
All structural analysis presented within this database uses a novel FXa structure, generated through stitching together the previously published
1P0S and 1XKA
structures, taken from the Protein Data Bank.
The complete FXa structure consists of the Gla , EGF-1, EGF-2 and SP domains.
Experimental Structures available for Human Coagulation Factor X
PDB |
Method |
Description |
Resolution |
Chain |
Position |
PDBsum |
|---|---|---|---|---|---|---|
| 1C5M | X-ray | Structural basis for selectivity of a small molecule, S1-binding, sub-micromolar inhibitor of urokinase type plasminogen activator. | 1.9 | D | 235-475 | >> |
| 1C5M | X-ray | Structural basis for selectivity of a small molecule, S1-binding, sub-micromolar inhibitor of urokinase type plasminogen activator. | 1.9 | F | 128-179 | >> |
| 1EZQ | X-ray | Crystal Structure of Human Coagulation Factor Xa complexed with RPR128515. | 2.2 | A | 235-468 | >> |
| 1EZQ | X-ray | Crystal Structure of Human Coagulation Factor Xa complexed with RPR128515. | 2.2 | B | 128-178 | >> |
| 1F0R | X-ray | Crystal Structure of Human Coagulation Factor Xa complexed with RPR208815. | 2.1 | A | 235-468 | >> |
| 1F0R | X-ray | Crystal Structure of Human Coagulation Factor Xa complexed with RPR208815. | 2.1 | B | 128-178 | >> |
| 1F0S | X-ray | Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707. | 2.1 | A | 235-468 | >> |
| 1F0S | X-ray | Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707. | 2.1 | B | 128-178 | >> |
| 1FAX | X-ray | Coagulation Factor Xa Inhibitor Complex. | 3.0 | A | 235-469 | >> |
| 1FAX | X-ray | Coagulation Factor Xa Inhibitor Complex. | 3.0 | L | 125-179 | >> |
| 1FJS | X-ray | Crystal Structure of the Inhibitor ZK-807834 (CI-1031) complexed with Factor Xa. | 1.9 | A | 235-468 | >> |
| 1FJS | X-ray | Crystal Structure of the Inhibitor ZK-807834 (CI-1031) complexed with Factor Xa. | 1.9 | L | 127-178 | >> |
| 1G2L | X-ray | Coagulation Factor Xa Inhibitor Complex. | 1.9 | A | 235-469 | >> |
| 1G2L | X-ray | Coagulation Factor Xa Inhibitor Complex. | 1.9 | B | 125-179 | >> |
| 1G2M | X-ray | Coagulation Factor Xa Inhibitor Complex. | 3.0 | A | 235-469 | >> |
| 1G2M | X-ray | Coagulation Factor Xa Inhibitor Complex. | 3.0 | B | 125-179 | >> |
| 1HCG | X-ray | Structure of Human (des(1-45)) Factor Xa at 2.2 Angstroms resolution. | 2.2 | A | 235-475 | >> |
| 1HCG | X-ray | Structure of Human (des(1-45)) Factor Xa at 2.2 Angstroms resolution. | 2.2 | B | 129-179 | >> |
| 1IOE | X-ray | Human coagulation factor Xa in complex with M55532. | 2.9 | A | 235-469 | >> |
| 1IOE | X-ray | Human coagulation factor Xa in complex with M55532. | 2.9 | L | 127-177 | >> |
| 1IQE | X-ray | Human coagulation factor Xa in complex with M55590. | 2.9 | A | 235-469 | >> |
| 1IQE | X-ray | Human coagulation factor Xa in complex with M55590. | 2.9 | L | 127-177 | >> |
| 1IQF | X-ray | Human coagulation factor Xa in complex with M55165. | 3.2 | A | 235-469 | >> |
| 1IQF | X-ray | Human coagulation factor Xa in complex with M55165. | 3.2 | L | 127-177 | >> |
| 1IQG | X-ray | Human coagulation factor Xa in complex with M55159. | 2.6 | A | 235-469 | >> |
| 1IQG | X-ray | Human coagulation factor Xa in complex with M55159. | 2.6 | L | 127-177 | >> |
| 1IQH | X-ray | Human coagulation factor Xa in complex with M55143. | 3.0 | A | 235-469 | >> |
| 1IQH | X-ray | Human coagulation factor Xa in complex with M55143. | 3.0 | L | 127-177 | >> |
| 1IQI | X-ray | Human coagulation factor Xa in complex with M55125. | 2.9 | A | 235-469 | >> |
| 1IQI | X-ray | Human coagulation factor Xa in complex with M55125. | 2.9 | L | 127-177 | >> |
| 1IQJ | X-ray | Human coagulation factor Xa in complex with M55124. | 3.0 | A | 235-469 | >> |
| 1IQJ | X-ray | Human coagulation factor Xa in complex with M55124. | 3.0 | L | 127-177 | >> |
| 1IQK | X-ray | Human coagulation factor Xa in complex with M55113. | 3.2 | A | 235-469 | >> |
| 1IQK | X-ray | Human coagulation factor Xa in complex with M55113. | 3.2 | L | 127-177 | >> |
| 1IQL | X-ray | Human coagulation factor Xa in complex with M54476. | 2.7 | A | 235-469 | >> |
| 1IQL | X-ray | Human coagulation factor Xa in complex with M54476. | 2.7 | L | 127-177 | >> |
| 1IQM | X-ray | Human coagulation factor Xa in complex with M54471. | 2.6 | A | 235-469 | >> |
| 1IQM | X-ray | Human coagulation factor Xa in complex with M54471. | 2.6 | L | 127-177 | >> |
| 1IQN | X-ray | Human coagulation factor Xa in complex with M55192. | 2.6 | A | 235-469 | >> |
| 1IQN | X-ray | Human coagulation factor Xa in complex with M55192. | 2.6 | L | 127-177 | >> |
| 1KSN | X-ray | Crystal Structure of Human Coagulation Factor XA Complexed with FXV673. | 2.1 | A | 235-468 | >> |
| 1KSN | X-ray | Crystal Structure of Human Coagulation Factor XA Complexed with FXV673. | 2.1 | B | 127-178 | >> |
| 1LPG | X-ray | Crystal Structure of FXa in complex with compound 79. | 2.0 | A | 126-178 | >> |
| 1LPG | X-ray | Crystal Structure of FXa in complex with compound 79. | 2.0 | B | 235-468 | >> |
| 1LPK | X-ray | Crystal Structure of FXa in complex with compound 125. | 2.2 | A | 126-178 | >> |
| 1LPK | X-ray | Crystal Structure of FXa in complex with compound 125. | 2.2 | B | 235-468 | >> |
| 1LPZ | X-ray | Crystal Structure of FXa in complex with compound 41. | 2.4 | A | 126-178 | >> |
| 1LPZ | X-ray | Crystal Structure of FXa in complex with compound 41. | 2.4 | B | 235-468 | >> |
| 1LQD | X-ray | Crystal Structure of FXa in complex with compound 45. | 2.7 | A | 126-178 | >> |
| 1LQD | X-ray | Crystal Structure of FXa in complex with compound 45. | 2.7 | B | 235-468 | >> |
| 1MQ5 | X-ray | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa. | 2.1 | A | 235-467 | >> |
| 1MQ5 | X-ray | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa. | 2.1 | L | 127-177 | >> |
| 1MQ6 | X-ray | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa. | 2.1 | A | 235-467 | >> |
| 1MQ6 | X-ray | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa. | 2.1 | L | 127-177 | >> |
| 1NFU | X-ray | Crystal Structure of Human Coagulation Factor Xa Complexed with RPR132747. | 2.0 | A | 235-468 | >> |
| 1NFU | X-ray | Crystal Structure of Human Coagulation Factor Xa Complexed with RPR132747. | 2.0 | B | 126-177 | >> |
| 1NFW | X-ray | Crystal Structure of Human Coagulation Factor Xa Complexed with RPR209685. | 2.1 | A | 235-468 | >> |
| 1NFW | X-ray | Crystal Structure of Human Coagulation Factor Xa Complexed with RPR209685. | 2.1 | B | 128-178 | >> |
| 1NFX | X-ray | Crystal structure of Human Coagulation Factor Xa complexed with RPR208944. | 2.1 | A | 235-468 | >> |
| 1NFX | X-ray | Crystal structure of Human Coagulation Factor Xa complexed with RPR208944. | 2.1 | B | 126-178 | >> |
| 1NFY | X-ray | Crystal structure of Human Coagulation Factor Xa complexed with RPR200095. | 2.1 | A | 235-468 | >> |
| 1NFY | X-ray | Crystal structure of Human Coagulation Factor Xa complexed with RPR200095. | 2.1 | B | 126-178 | >> |
| 1P0S | X-ray | Crystal Structure of Blood Coagulation Factor Xa in Complex with Ecotin M84R. | 2.8 | L | 43-178 | >> |
| 1P0S | X-ray | Crystal Structure of Blood Coagulation Factor Xa in Complex with Ecotin M84R. | 2.8 | H | 235-469 | >> |
| 1V3X | X-ray | Factor Xa in complex with the inhibitor 1-[6-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl] carbonyl-2-carbamoyl-4-(6-chloronaphth-2-ylsulphonyl)piperazine. | 2.2 | A | 235-467 | >> |
| 1V3X | X-ray | Factor Xa in complex with the inhibitor 1-[6-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl] carbonyl-2-carbamoyl-4-(6-chloronaphth-2-ylsulphonyl)piperazine. | 2.2 | B | 127-178 | >> |
| 1WU1 | X-ray | Factor Xa in complex with the inhibitor 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl) pyrimidin-2-yl]carbonyl]piperazine. | 2.3 | A | 235-467 | >> |
| 1WU1 | X-ray | Factor Xa in complex with the inhibitor 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl) pyrimidin-2-yl]carbonyl]piperazine. | 2.3 | B | 125-178 | >> |
| 1XKA | X-ray | Factor Xa complexed with a synthetic inhibitor FX-2212A, ((2S)-(3'-amidino-3-biphenyl)-5-(4-pyridylamino)pentanoic acid. | 2.3 | L | 89-179 | >> |
| 1XKA | X-ray | Factor Xa complexed with a synthetic inhibitor FX-2212A, ((2S)-(3'-amidino-3-biphenyl)-5-(4-pyridylamino)pentanoic acid. | 2.3 | C | 235-469 | >> |
| 1XKB | X-ray | Factor Xa complexed with a synthetic inhibitor FX-2212A, ((2S)-(3'-amidino-3-biphenyl)-5-(4-pyridylamino)pentanoic acid. | 2.4 | A/B | 88-179 | >> |
| 1XKB | X-ray | Factor Xa complexed with a synthetic inhibitor FX-2212A, ((2S)-(3'-amidino-3-biphenyl)-5-(4-pyridylamino)pentanoic acid. | 2.4 | C/D | 235-469 | >> |
| 1Z6E | X-ray | Factor XA in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol-5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; DPC906; BMS-561389). | 1.8 | A | 235-468 | >> |
| 1Z6E | X-ray | Factor XA in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol-5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; DPC906; BMS-561389). | 1.8 | L | 127-178 | >> |
| 2BMG | X-ray | Crystal structure of factor Xa in complex with 50. | 2.7 | A | 126-178 | >> |
| 2BMG | X-ray | Crystal structure of factor Xa in complex with 50. | 2.7 | B | 235-468 | >> |
| 2BOH | X-ray | Crystal structure of factor Xa in complex with compound "1". | 2.2 | A | 126-179 | >> |
| 2BOH | X-ray | Crystal structure of factor Xa in complex with compound "1". | 2.2 | B | 235-469 | >> |
| 2BOK | X-ray | Factor Xa - cation complex. | 1.6 | A | 235-468 | >> |
| 2BOK | X-ray | Factor Xa - cation complex. | 1.6 | L | 127-178 | >> |
| 2BQ6 | X-ray | Crystal structure of factor Xa in complex with 21. | 3.0 | A | 126-177 | >> |
| 2BQ6 | X-ray | Crystal structure of factor Xa in complex with 21. | 3.0 | B | 220-468 | >> |
| 2BQ7 | X-ray | Crystal structure of factor Xa in complex with 43. | 2.2 | A | 126-177 | >> |
| 2BQ7 | X-ray | Crystal structure of factor Xa in complex with 43. | 2.2 | B | 220-468 | >> |
| 2BQW | X-ray | Crystal structure of factor Xa in complex with compound 45. | 2.9 | A | 126-177 | >> |
| 2BQW | X-ray | Crystal structure of factor Xa in complex with compound 45. | 2.9 | B | 235-468 | >> |
| 2CJI | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | A | 235-468 | >> |
| 2CJI | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | B | 127-178 | >> |
| 2D1J | X-ray | Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide. | 2.2 | A | 235-467 | >> |
| 2D1J | X-ray | Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide. | 2.2 | B | 125-178 | >> |
| 2EI6 | X-ray | Factor Xa in complex with the inhibitor (-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.3 | A | 235-467 | >> |
| 2EI6 | X-ray | Factor Xa in complex with the inhibitor (-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.3 | B | 125-178 | >> |
| 2EI7 | X-ray | Factor Xa in complex with the inhibitor trans-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.3 | A | 235-467 | >> |
| 2EI7 | X-ray | Factor Xa in complex with the inhibitor trans-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.3 | B | 125-178 | >> |
| 2EI8 | X-ray | Factor Xa in complex with the inhibitor (1S,2R,4S)-N1-[(5-chloroindol-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.1 | A | 235-467 | >> |
| 2EI8 | X-ray | Factor Xa in complex with the inhibitor (1S,2R,4S)-N1-[(5-chloroindol-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine. | 2.1 | B | 125-178 | >> |
| 2FZZ | X-ray | Factor Xa in complex with the inhibitor 1-(3-amino-1,2-benzisoxazol-5-yl)-6-(2'-(((3r)-3-hydroxy-1-pyrrolidinyl)methyl)-4-biphenylyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7h-pyrazolo[3,4-c]pyridin-7-one. | 2.2 | A | 235-468 | >> |
| 2FZZ | X-ray | Factor Xa in complex with the inhibitor 1-(3-amino-1,2-benzisoxazol-5-yl)-6-(2'-(((3r)-3-hydroxy-1-pyrrolidinyl)methyl)-4-biphenylyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7h-pyrazolo[3,4-c]pyridin-7-one. | 2.2 | L | 127-178 | >> |
| 2G00 | X-ray | Factor Xa in complex with the inhibitor 3-(6-(2'-((dimethylamino)methyl)-4-biphenylyl)-7-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)benzamide. | 2.1 | A | 235-468 | >> |
| 2G00 | X-ray | Factor Xa in complex with the inhibitor 3-(6-(2'-((dimethylamino)methyl)-4-biphenylyl)-7-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)benzamide. | 2.1 | L | 127-178 | >> |
| 2GD4 | X-ray | Crystal Structure of the Antithrombin-S195A Factor Xa-Pentasaccharide Complex. | 3.3 | A/L | 126-179 | >> |
| 2GD4 | X-ray | Crystal Structure of the Antithrombin-S195A Factor Xa-Pentasaccharide Complex. | 3.3 | B/H | 235-473 | >> |
| 2H9E | X-ray | Crystal Structure of FXa/selectide/NAPC2 ternary complex. | 2.2 | H | 235-467 | >> |
| 2H9E | X-ray | Crystal Structure of FXa/selectide/NAPC2 ternary complex. | 2.2 | L | 129-176 | >> |
| 2J2U | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 1.9 | A | 235-467 | >> |
| 2J2U | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 1.9 | B | 126-177 | >> |
| 2J34 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.0 | A | 235-468 | >> |
| 2J34 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.0 | B | 127-178 | >> |
| 2J38 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | A | 235-468 | >> |
| 2J38 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | B | 127-177 | >> |
| 2J4I | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 1.8 | A | 235-468 | >> |
| 2J4I | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 1.8 | B | 126-177 | >> |
| 2J94 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | A | 235-468 | >> |
| 2J94 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.1 | B | 126-177 | >> |
| 2J95 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.0 | A | 235-468 | >> |
| 2J95 | X-ray | Crystal structure of a Human Factor Xa inhibitor complex. | 2.0 | B | 127-178 | >> |
| 2JKH | X-ray | Factor Xa - cation inhibitor complex. | 1.2 | A | 235-468 | >> |
| 2JKH | X-ray | Factor Xa - cation inhibitor complex. | 1.2 | L | 127-180 | >> |
| 2P16 | X-ray | Factor Xa in complex with the inhibitor Apixaban (BMS-562247). | 2.3 | A | 235-468 | >> |
| 2P16 | X-ray | Factor Xa in complex with the inhibitor Apixaban (BMS-562247). | 2.3 | L | 127-178 | >> |
| 2P3F | X-ray | Crystal structure of the factor Xa/NAP5 complex. | 3.1 | H | 235-469 | >> |
| 2P3F | X-ray | Crystal structure of the factor Xa/NAP5 complex. | 3.1 | L | 128-178 | >> |
| 2P3T | X-ray | Crystal structure of human factor XA complexed with 3-Chloro-4-(2-methylamino-imidazol-1-ylmethyl)-thiophene-2-carboxylic acid [4-chloro-2-(5-chloro-pyridin-2-ylcarbamoyl)-6-methoxy-phenyl]-amide. | 1.9 | A | 127-178 | >> |
| 2P3T | X-ray | Crystal structure of human factor XA complexed with 3-Chloro-4-(2-methylamino-imidazol-1-ylmethyl)-thiophene-2-carboxylic acid [4-chloro-2-(5-chloro-pyridin-2-ylcarbamoyl)-6-methoxy-phenyl]-amide. | 1.9 | B | 235-467 | >> |
| 2P3U | X-ray | Crystal structure of human factor XA complexed with 3-chloro-N-(4-chloro-2-{[(5-chloropyridin-2-yl)amino]carbonyl}-6-methoxyphenyl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]thiophene-2-carboxamide {Pfizer 320663}. | 1.6 | A | 127-177 | >> |
| 2P3U | X-ray | Crystal structure of human factor XA complexed with 3-chloro-N-(4-chloro-2-{[(5-chloropyridin-2-yl)amino]carbonyl}-6-methoxyphenyl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]thiophene-2-carboxamide {Pfizer 320663}. | 1.6 | B | 235-467 | >> |
| 2P93 | X-ray | Factor xa in complex with the inhibitor 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide. | 1.9 | A | 235-468 | >> |
| 2P93 | X-ray | Factor xa in complex with the inhibitor 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide. | 1.9 | L | 127-178 | >> |
| 2P94 | X-ray | Factor xa in complex with the inhibitor 3-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-yl)benzamido)cyclohexyl)-1H-indole-6-carboxamide. | 1.8 | A | 235-468 | >> |
| 2P94 | X-ray | Factor xa in complex with the inhibitor 3-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-yl)benzamido)cyclohexyl)-1H-indole-6-carboxamide. | 1.8 | L | 127-178 | >> |
| 2P95 | X-ray | Factor xa in complex with the inhibitor 5-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-YL)benzamido) cyclopentyl)thiophene-2-carboxamide. | 2.2 | A | 235-468 | >> |
| 2P95 | X-ray | Factor xa in complex with the inhibitor 5-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-YL)benzamido) cyclopentyl)thiophene-2-carboxamide. | 2.2 | L | 127-178 | >> |
| 2PHB | X-ray | An Orally Efficacious Factor Xa Inhibitor. | 2.3 | A | 235-468 | >> |
| 2PHB | X-ray | An Orally Efficacious Factor Xa Inhibitor. | 2.3 | B | 128-178 | >> |
| 2PR3 | X-ray | Factor XA inhibitor. | 1.5 | A | 235-468 | >> |
| 2PR3 | X-ray | Factor XA inhibitor. | 1.5 | B | 129-178 | >> |
| 2Q1J | X-ray | The discovery of glycine and related amino acid-based factor xa inhibitors. | 1.9 | A | 235-468 | >> |
| 2Q1J | X-ray | The discovery of glycine and related amino acid-based factor xa inhibitors. | 1.9 | B | 128-178 | >> |
| 2RA0 | X-ray | X-ray Structure of FXa in complex with 7-fluoroindazole. | 2.3 | A | 235-468 | >> |
| 2RA0 | X-ray | X-ray Structure of FXa in complex with 7-fluoroindazole. | 2.3 | L | 129-178 | >> |
| 2UWL | X-ray | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa. | 1.9 | A | 235-468 | >> |
| 2UWL | X-ray | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa. | 1.9 | B | 126-177 | >> |
| 2UWO | X-ray | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa. | 1.7 | A | 235-468 | >> |
| 2UWO | X-ray | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa. | 1.7 | B | 126-177 | >> |
| 2UWP | X-ray | Factor Xa inhibitor complex. | 1.7 | A | 235-469 | >> |
| 2UWP | X-ray | Factor Xa inhibitor complex. | 1.7 | B | 126-177 | >> |
| 2VH0 | X-ray | Structure and property based design of factor Xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. | 1.7 | A | 235-468 | >> |
| 2VH0 | X-ray | Structure and property based design of factor Xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. | 1.7 | B | 126-177 | >> |
| 2VH6 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. | 1.9 | A | 235-468 | >> |
| 2VH6 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. | 1.9 | B | 125-178 | >> |
| 2VVC | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.9 | A/B | 235-467 | >> |
| 2VVC | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.9 | K/L | 126-179 | >> |
| 2VVU | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 2.3 | A | 235-468 | >> |
| 2VVU | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 2.3 | L | 126-180 | >> |
| 2VVV | X-ray | Aminopyrrolidine-related triazole Factor Xa inhibitor. | 1.7 | A | 235-468 | >> |
| 2VVV | X-ray | Aminopyrrolidine-related triazole Factor Xa inhibitor. | 1.7 | L | 127-180 | >> |
| 2VWL | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.8 | A | 235-469 | >> |
| 2VWL | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.8 | L | 129-179 | >> |
| 2VWM | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.9 | A/B | 235-467 | >> |
| 2VWM | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.9 | K/L | 126-179 | >> |
| 2VWN | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.6 | A | 235-469 | >> |
| 2VWN | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.6 | L | 128-179 | >> |
| 2VWO | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.6 | A | 235-469 | >> |
| 2VWO | X-ray | Aminopyrrolidine Factor Xa inhibitor. | 1.6 | L | 128-179 | >> |
| 2W26 | X-ray | Factor Xa in complex with BAY59-7939. | 2.0 | A | 235-468 | >> |
| 2W26 | X-ray | Factor Xa in complex with BAY59-7939. | 2.0 | B | 127-177 | >> |
| 2W3I | X-ray | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2. | 1.9 | A | 235-468 | >> |
| 2W3I | X-ray | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2. | 1.9 | B | 128-178 | >> |
| 2W3K | X-ray | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 1. | 2.0 | A | 235-468 | >> |
| 2W3K | X-ray | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 1. | 2.0 | B | 128-178 | >> |
| 2WYG | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. | 1.8 | A | 235-468 | >> |
| 2WYG | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. | 1.8 | B | 126-177 | >> |
| 2WYJ | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. | 2.3 | A | 235-467 | >> |
| 2WYJ | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. | 2.3 | B | 126-177 | >> |
| 2XBV | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.6 | A | 235-469 | >> |
| 2XBV | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.6 | L | 129-179 | >> |
| 2XBW | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.7 | A | 235-469 | >> |
| 2XBW | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.7 | L | 129-179 | >> |
| 2XBX | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.8 | A | 235-469 | >> |
| 2XBX | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.8 | L | 129-179 | >> |
| 2XBY | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 2.0 | A | 235-469 | >> |
| 2XBY | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 2.0 | L | 129-179 | >> |
| 2XC0 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 2.0 | A | 235-469 | >> |
| 2XC0 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 2.0 | L | 129-179 | >> |
| 2XC4 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.6 | A | 235-468 | >> |
| 2XC4 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.6 | L | 127-180 | >> |
| 2XC5 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.7 | A | 235-469 | >> |
| 2XC5 | X-ray | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor. | 1.7 | L | 129-179 | >> |
| 2Y5F | X-ray | Factor Xa-cation inhibitor complex. | 1.2 | A | 235-468 | >> |
| 2Y5F | X-ray | Factor Xa-cation inhibitor complex. | 1.2 | L | 127-180 | >> |
| 2Y5G | X-ray | Factor Xa-cation inhibitor complex. | 1.2 | A | 235-468 | >> |
| 2Y5G | X-ray | Factor Xa-cation inhibitor complex. | 1.2 | L | 127-180 | >> |
| 2Y5H | X-ray | Factor Xa-cation inhibitor complex. | 1.3 | A | 235-468 | >> |
| 2Y5H | X-ray | Factor Xa-cation inhibitor complex. | 1.3 | L | 127-180 | >> |
| 2Y7X | X-ray | The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. | 1.9 | A | 235-469 | >> |
| 2Y7X | X-ray | The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. | 1.9 | B | 126-178 | >> |
| 2Y7Z | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.8 | A | 235-469 | >> |
| 2Y7Z | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.8 | B | 126-178 | >> |
| 2Y80 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.9 | A | 235-469 | >> |
| 2Y80 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.9 | B | 126-178 | >> |
| 2Y81 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.7 | A | 235-467 | >> |
| 2Y81 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 1.7 | B | 126-178 | >> |
| 2Y82 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 2.2 | A | 235-469 | >> |
| 2Y82 | X-ray | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. | 2.2 | B | 126-178 | >> |
| 3CEN | X-ray | Factor XA in complex with the inhibitor N-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide. | 1.6 | A | 235-468 | >> |
| 3CEN | X-ray | Factor XA in complex with the inhibitor N-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide. | 1.6 | L | 127-178 | >> |
| 3CS7 | X-ray | Factor Xa in complex with the inhibtor 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one. | 2.2 | A | 235-468 | >> |
| 3CS7 | X-ray | Factor Xa in complex with the inhibtor 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one. | 2.2 | L | 127-178 | >> |
| 3ENS | X-ray | Crystal structure of human FXA in complex with methyl (2Z)-3-[(3-chloro-1H-indol-7-yl)amino]-2-cyano-3-{[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate. | 2.3 | A/C | 90-178 | >> |
| 3ENS | X-ray | Crystal structure of human FXA in complex with methyl (2Z)-3-[(3-chloro-1H-indol-7-yl)amino]-2-cyano-3-{[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate. | 2.3 | B/D | 235-472 | >> |
| 3FFG | X-ray | Factor Xa in complex with the inhibitor ((R)-6-(2'-((3-hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-C]pyridin-7(4H)-one. | 1.5 | A | 235-468 | >> |
| 3FFG | X-ray | Factor Xa in complex with the inhibitor ((R)-6-(2'-((3-hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-C]pyridin-7(4H)-one. | 1.5 | L | 127-178 | >> |
| 3HPT | X-ray | Crystal structure of human FxA in complex with (S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine. | 2.1 | A/C | 90-178 | >> |
| 3HPT | X-ray | Crystal structure of human FxA in complex with (S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine. | 2.1 | B/D | 235-472 | >> |
| 3IIT | X-ray | Factor XA in complex with a cis-1,2-diaminocyclohexane derivative. | 1.8 | A | 235-467 | >> |
| 3IIT | X-ray | Factor XA in complex with a cis-1,2-diaminocyclohexane derivative. | 1.8 | B | 125-178 | >> |
| 3K9X | X-ray | X-Ray crystal structure of human FXa in complex with (S)-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide. | 1.9 | A/C | 90-178 | >> |
| 3K9X | X-ray | X-Ray crystal structure of human FXa in complex with (S)-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide. | 1.9 | B/D | 235-472 | >> |
| 3KL6 | X-ray | Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor. | 1.4 | A | 235-466 | >> |
| 3KL6 | X-ray | Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor. | 1.4 | B | 127-176 | >> |
| 3KQB | X-ray | Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide. | 2.2 | A | 235-468 | >> |
| 3KQB | X-ray | Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide. | 2.2 | L | 127-178 | >> |
| 3KQC | X-ray | Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.2 | A | 235-468 | >> |
| 3KQC | X-ray | Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.2 | L | 127-178 | >> |
| 3KQD | X-ray | Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.7 | A | 235-468 | >> |
| 3KQD | X-ray | Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.7 | L | 127-178 | >> |
| 3KQE | X-ray | Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.3 | A | 235-468 | >> |
| 3KQE | X-ray | Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one. | 2.3 | L | 127-178 | >> |
| 3LIW | X-ray | Factor Xa in complex with (R)-2-(1-adamantylcarbamoylamino)-3-(3-carbamidoyl-phenyl)-N-phenethyl-propionic acid amide. | 2.2 | A | 235-468 | >> |
| 3LIW | X-ray | Factor Xa in complex with (R)-2-(1-adamantylcarbamoylamino)-3-(3-carbamidoyl-phenyl)-N-phenethyl-propionic acid amide. | 2.2 | B | 128-178 | >> |
| 3M36 | X-ray | Factor XA in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423). | 2.1 | A | 235-468 | >> |
| 3M36 | X-ray | Factor XA in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423). | 2.1 | L | 127-178 | >> |
| 3M37 | X-ray | Factor XA in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC602). | 1.9 | A | 235-468 | >> |
| 3M37 | X-ray | Factor XA in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC602). | 1.9 | L | 127-178 | >> |
| 3Q3K | X-ray | Factor Xa in complex with a phenylenediamine derivative. | 2.0 | A | 235-467 | >> |
| 3Q3K | X-ray | Factor Xa in complex with a phenylenediamine derivative. | 2.0 | B | 126-177 | >> |
| 3SW2 | X-ray | X-ray crystal structure of human FXA in complex with 6-chloro-N-((3S)-2-oxo-1-(2-oxo-2-((5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide. | 2.4 | A | 122-177 | >> |
| 3SW2 | X-ray | X-ray crystal structure of human FXA in complex with 6-chloro-N-((3S)-2-oxo-1-(2-oxo-2-((5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide. | 2.4 | B | 235-467 | >> |
| 3TK5 | X-ray | Factor Xa in complex with D102-4380. | 2.2 | A | 235-467 | >> |
| 3TK5 | X-ray | Factor Xa in complex with D102-4380. | 2.2 | B | 125-178 | >> |
| 3TK6 | X-ray | Factor Xa in complex with D46-5241. | 1.8 | A | 235-467 | >> |
| 3TK6 | X-ray | Factor Xa in complex with D46-5241. | 1.8 | B | 125-178 | >> |
| 4A7I | X-ray | Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor. | 2.4 | A | 126-178 | >> |
| 4A7I | X-ray | Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor. | 2.4 | B | 235-468 | >> |
| 4BTI | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 58. | 2.3 | A/E | 126-179 | >> |
| 4BTI | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 58. | 2.3 | B/F | 235-469 | >> |
| 4BTT | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 31. | 2.5 | A/E | 126-176 | >> |
| 4BTT | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 31. | 2.5 | B/F | 235-469 | >> |
| 4BTU | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 57. | 2.3 | A/E | 126-179 | >> |
| 4BTU | X-ray | Factor Xa in complex with the dual thrombin-FXa inhibitor 57. | 2.3 | B/F | 235-469 | >> |
| 4Y6D | X-ray | Factor Xa complex with GTC000101. | 1.5 | A | 235-468 | >> |
| 4Y6D | X-ray | Factor Xa complex with GTC000101. | 1.5 | B | 126-177 | >> |
| 4Y71 | X-ray | Factor Xa complex with GTC000398. | 1.8 | A | 235-468 | >> |
| 4Y71 | X-ray | Factor Xa complex with GTC000398. | 1.8 | B | 126-177 | >> |
| 4Y76 | X-ray | Factor Xa complex with GTC000401. | 2.0 | A | 235-468 | >> |
| 4Y76 | X-ray | Factor Xa complex with GTC000401. | 2.0 | B | 126-178 | >> |
| 4Y79 | X-ray | Factor Xa complex with GTC000406. | 2.1 | A | 235-468 | >> |
| 4Y79 | X-ray | Factor Xa complex with GTC000406. | 2.1 | B | 126-178 | >> |
| 4Y7A | X-ray | Factor Xa complex with GTC000422. | 1.9 | A | 235-468 | >> |
| 4Y7A | X-ray | Factor Xa complex with GTC000422. | 1.9 | B | 126-178 | >> |
| 4Y7B | X-ray | Factor Xa complex with GTC000441. | 1.7 | A | 235-468 | >> |
| 4Y7B | X-ray | Factor Xa complex with GTC000441. | 1.7 | B | 126-178 | >> |
| 4ZH8 | X-ray | Factor Xa complex with GTC000006. | 1.8 | A | 235-468 | >> |
| 4ZH8 | X-ray | Factor Xa complex with GTC000006. | 1.8 | B | 127-178 | >> |
| 4ZHA | X-ray | Factor Xa complex with GTC000102. | 1.8 | A | 235-468 | >> |
| 4ZHA | X-ray | Factor Xa complex with GTC000102. | 1.8 | B | 126-177 | >> |
| 5K0H | X-ray | Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide. | 2.2 | A | 235-468 | >> |
| 5K0H | X-ray | Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide. | 2.2 | B | 128-178 | >> |
| 5VOE | X-ray | DesGla-XaS195A Bound to Aptamer 11F7t. | 2.0 | H | 235-467 | >> |
| 5VOE | X-ray | DesGla-XaS195A Bound to Aptamer 11F7t. | 2.0 | L | 128-178 | >> |
| 5VOF | X-ray | DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban. | 2.2 | H | 235-467 | >> |
| 5VOF | X-ray | DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban. | 2.2 | L | 128-178 | >> |